China-based global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) announced on Wednesday that it has named Xu Wang as its new chief executive officer (CEO).
Wang succeeds Dave Chenn and Dr Hui Shao, who has stepped down from the company's interim CEO and co-CEO positions, respectively.
Wang has worked as the firm's chief operation officer since June 2024, and will no longer assume such role upon becoming the company's chief executive officer.
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
Centivax raises USD45m to commercialise universal flu vaccine
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval